LLY vs PFE
Eli Lilly and Company vs Pfizer Inc. — AI-powered side-by-side comparison
LLY
Eli Lilly and Company
56
Watch
VS
| Metric | LLY | PFE |
|---|
| AI Score |
56
|
53
|
| Price |
$1,178.18
|
$28.27
|
| P/E Ratio |
39.45×
|
37.37×
|
| ROE |
77.8%
|
9.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
83.4%
|
71.3%
|
| Debt / Equity |
1.62×
|
0.74×
|
| Dividend Yield |
0.6%
|
6.1%
|
| RSI (14) |
57.6
|
57.6
|
| Beta |
0.454
|
0.276
|
| Expected Upside |
+6.0%
|
+1.6%
|
AI Committee View
Current Innellis committee reasoning for LLY versus PFE.
LLY leads by 3 points.
LLY scores 56/100 (Watch) versus PFE at 53/100 (Watch).
LLY Committee View
67% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 49.6% yoy -- genuine top-line momentum. Risk Analyst remains cautious — high leverage (debt-to-equity 1.60) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 92.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 49.6% YoY -- genuine top-line momentum — Growth
- EPS growing 94.6% YoY — Growth
Bear Case
- P/E of 40.9 is expensive by classic value standards — Value
- Price-to-book of 38.3x prices in significant intangible value — Value
- Debt-to-equity of 1.60 adds balance-sheet risk to the value case — Value
PFE Committee View
40% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Dividend yield of 5.4% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 36.9 is moderate-to-rich — Value
- ROE of only 4.9% -- cheap may mean cheap for a reason — Value
- Revenue declining -0.2% YoY -- this is not a growth story right now — Growth